Table 4.
Joint Effect Survival Analysis
| Gene | Patients | OS | |||
|---|---|---|---|---|---|
| (n=121) | HR (95% CI) | Crude P | HR (95% CI) | Adjusted Pa | |
| Low ESPL1& GTSE1& BUB1B & PRC1 & KIF23 & TOP2A | 37 | Ref | Ref | ||
| Not all high or low | 46 | 1.285 (0.532–3.103) | 0.577 | 1.384 (0.561–3.414) | 0.481 |
| High ESPL1 & GTSE1 & BUB1B& PRC1 & KIF23 & TOP2A | 38 | 3.742 (1.676–8.358) | <0.001 | 3.376 (1.463–7.790) | 0.004 |
Note: aAdjusted P, adjustment for BCLC stage, Edmondson grade, age, tumor size and AFP.
Abbreviations: ESPL1, extra spindle pole bodies-like 1; GTSE1, genes G-2 and S-phase expressed 1; KIF18B, kinesin family member 18B; BUB1B, mitotic checkpoint serine/threonine kinase B; GINS1, GINS complex subunit 1; PRC1, protein regulator of cytokinesis 1; KIF23, kinesin family member 23; KIF18A, TOP2A, DNA topoisomerase II alpha; NEK2, NIMA related kinase 2.